Holen Sie sich die Stockscreener-App
168.83
2.40%
4.15
Handel nachbörslich:
169.60
0.77
+0.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$164.68
Offen:
$164.4
24-Stunden-Volumen:
1.84M
Relative Volume:
1.08
Marktkapitalisierung:
$58.09B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.15
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+5.69%
1M Leistung:
+17.93%
6M Leistung:
+34.28%
1J Leistung:
+6.77%
1-Tages-Spanne:
$163.00
$170.78
1-Wochen-Bereich:
$158.05
$170.78
52-Wochen-Spanne:
$110.03
$170.78
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
168.83 | 24.16B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,030.36 | 914.44B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
200.03 | 480.85B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
343.99 | 184.00B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
233.88 | 413.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
96.47 | 230.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
How analysts rate Biogen Inc. stock todayWeekly Risk Report & Consistent Profit Alerts - newser.com
Does Biogen’s (BIIB) Rare Disease Pipeline Gain Momentum with New Dravet Study Data? - simplywall.st
Biogen’s SWOT analysis: mixed outlook as Alzheimer’s drug gains traction amid stock valuation concerns - Investing.com
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen, Stoke Release Final BUTTERFLY Study Data - Nasdaq
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom - TradingView
Biogen Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Stu - GuruFocus
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study - GuruFocus
Biogen Says EU Committee Recommends Approval of High Dose Nusinersen Regimen - MarketScreener
Biogen Completes Acquisition of Alcyone Therapeutics - FinSMEs
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
European regulator backs high-dose nusinersen for spinal muscular atrophy By Investing.com - Investing.com Australia
European regulator backs high-dose nusinersen for spinal muscular atrophy - Investing.com
Biogen (BIIB) Advances High Dose Spinal Muscular Atrophy Treatme - GuruFocus
Biogen acquires Alcyone to boost CNS drug delivery - Yahoo Finance
High dose regimen of Nusinersen receives positive CHMP opinion for the treatment of spinal muscular atrophy - MarketScreener
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy - Biogen
Why Biogen Inc. (IDP) stock stays on top picksWeekly Trend Recap & AI Driven Price Predictions - newser.com
Why Biogen Inc. (IDP) stock benefits from AI revolutionTrade Ideas & Growth Focused Entry Reports - newser.com
Why Biogen Inc. stock is considered a top pickEarnings Trend Report & Scalable Portfolio Growth Methods - newser.com
Chart based exit strategy for Biogen Inc.July 2025 Breakouts & Smart Money Movement Tracker - newser.com
Key metrics from Biogen Inc.’s quarterly dataRisk Management & Daily Risk Controlled Trade Plans - newser.com
Will Biogen Inc. (IDP) stock benefit from commodity supercycle2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
STATE STREET CORP Reduces Stake in Biogen Inc: A Detailed Analys - GuruFocus
Analyzing Biogen Inc. with multi timeframe chartsJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Biogen completes acquisition of Alcyone Therapeutics By Investing.com - Investing.com India
Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio - Quiver Quantitative
Biogen completes acquisition of Alcyone Therapeutics - MarketScreener
How Biogen Inc. (IDP) stock behaves in tightening cyclesWeekly Profit Analysis & Fast Entry and Exit Trade Plans - newser.com
Discipline and Rules-Based Execution in BIIB Response - news.stocktradersdaily.com
Biogen stock hits 52-week high at 167.87 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 167.87 USD - Investing.com India
How to escape a deep drawdown in Biogen Inc.Trade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Biogen (BIIB) Gains UK Approval for LEQEMBI Maintenance Dosing - GuruFocus
'LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - The Manila Times
Eisai and Biogen's LEQEMBI® Receives Approval for Once Every Four Weeks IV Maintenance Dosing in the UK - Quiver Quantitative
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - Biogen
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - GlobeNewswire Inc.
Biogen at TD Cowen Summit: Strategic Focus on I&I and Kidney Innovation - Investing.com
Biogen (BIIB) Valuation in Focus Following Q3 2025 Results and Key Medical Conference Updates - simplywall.st
Biogen Inc: Time to Ride the Surge? - timothysykes.com
What the Options Market Tells Us About Biogen - Benzinga
Biogen Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month - Yahoo Finance
Biogen’s Alzheimer’s Bet: Can the EVOKE Trial Redefine the Future of Neurology? - Smartkarma
Institutional scanner results for Biogen Inc.Earnings Risk Report & AI Driven Stock Reports - newser.com
Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Should you wait for a breakout in Biogen Inc.July 2025 Fed Impact & High Accuracy Investment Signals - newser.com
How Biogen’s (BIIB) Strong Q3 Earnings and New Product Growth Could Shape Its Investment Outlook - simplywall.st
Alzheimer’s drug uptake hits its stride after a sluggish start - PharmaVoice
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer |
Oct 02 '25 |
Option Exercise |
0.00 |
26 |
0 |
503 |
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
2.40%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):